ZAI LAB LIMITED Increase (Decrease) in Deferred Revenue
ZAI LAB LIMITED (ZLAB) reported Increase (Decrease) in Deferred Revenue of $2.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-06
- ZAI LAB LIMITED increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was $11.00K, a 97.07% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was $2.35M.
- ZAI LAB LIMITED increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was $384.00K, a 95.28% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was -$4.00K.
- ZAI LAB LIMITED increase (decrease) in deferred revenue for fiscal 2025 was $745.00K, a 88.69% decline from fiscal 2024.
- ZAI LAB LIMITED increase (decrease) in deferred revenue for fiscal 2024 was $6.59M, a 41.08% decline from fiscal 2023.
- ZAI LAB LIMITED increase (decrease) in deferred revenue for fiscal 2023 was $11.18M.
- ZAI LAB LIMITED increase (decrease) in deferred revenue for fiscal 2022 was -$1.38M, a 112.37% decline from fiscal 2021.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.36M 10-Q · filed 2026-08-06 | $2.75M derived: sum of 3 quarters · filed 2026-08-06 | $2.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.35M 10-Q · filed 2026-05-07 | $2.74M derived: sum of 2 quarters · filed 2026-05-07 | $2.73M derived: sum of 3 quarters · filed 2026-05-07 | $3.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $384.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $380.00K derived: sum of 2 quarters · filed 2026-02-26 | $756.00K derived: sum of 3 quarters · filed 2026-08-06 | $745.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $372.00K derived: sum of 2 quarters · filed 2026-08-06 | $361.00K 10-Q · filed 2025-11-06 | $8.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $376.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $365.00K 10-Q · filed 2026-08-06 | $8.50M derived: sum of 3 quarters · filed 2026-08-06 | $8.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$11.00K 10-Q · filed 2026-05-07 | $8.13M derived: sum of 2 quarters · filed 2026-05-07 | $8.13M derived: sum of 3 quarters · filed 2026-05-07 | $8.13M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $8.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.14M derived: sum of 2 quarters · filed 2026-02-26 | $8.14M derived: sum of 3 quarters · filed 2026-02-26 | $6.59M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.00K derived: sum of 2 quarters · filed 2025-11-06 | -$1.55M 10-Q · filed 2025-11-06 | $14.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.55M 10-Q · filed 2025-08-07 | $14.00K derived: sum of 3 quarters · filed 2026-02-26 | -$269.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$1.55M 10-Q · filed 2025-05-08 | $12.00K derived: sum of 2 quarters · filed 2026-02-26 | -$271.00K derived: sum of 3 quarters · filed 2026-02-26 | -$208.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.28M derived: sum of 2 quarters · filed 2026-02-26 | $1.34M derived: sum of 3 quarters · filed 2026-02-26 | $11.18M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$283.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$220.00K derived: sum of 2 quarters · filed 2024-11-12 | $9.62M 10-Q · filed 2024-11-12 | $7.77M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $63.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $9.90M 10-Q · filed 2024-08-06 | $8.05M derived: sum of 3 quarters · filed 2025-02-27 | $9.85M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $9.84M 10-Q · filed 2024-05-08 | $7.99M derived: sum of 2 quarters · filed 2025-02-27 | $9.79M derived: sum of 3 quarters · filed 2025-02-27 | $8.34M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$54.00K derived: sum of 2 quarters · filed 2025-02-27 | -$1.50M derived: sum of 3 quarters · filed 2025-02-27 | -$1.38M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $352.00K derived: sum of 2 quarters · filed 2023-11-07 | $470.00K 10-Q · filed 2023-11-07 | $10.76M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$1.32M 10-Q · filed 2023-08-07 | $8.96M derived: sum of 3 quarters · filed 2024-02-27 | $8.89M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $118.00K 10-Q · filed 2023-05-09 | $10.40M derived: sum of 2 quarters · filed 2024-02-27 | $10.34M derived: sum of 3 quarters · filed 2024-02-27 | $11.39M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $10.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $10.22M derived: sum of 2 quarters · filed 2024-02-27 | $11.27M derived: sum of 3 quarters · filed 2024-02-27 | $11.15M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$67.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $985.00K derived: sum of 2 quarters · filed 2022-11-09 | $863.00K 10-Q · filed 2022-11-09 | $1.55M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $930.00K 10-Q · filed 2022-08-09 | $1.61M derived: sum of 3 quarters · filed 2023-03-01 | $2.21M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$122.00K 10-Q · filed 2022-05-10 | $561.00K derived: sum of 2 quarters · filed 2023-03-01 | $1.16M derived: sum of 3 quarters · filed 2023-03-01 | $13.88M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $683.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.28M derived: sum of 2 quarters · filed 2023-03-01 | $14.00M derived: sum of 3 quarters · filed 2023-03-01 | $14.29M 10-K · filed 2023-03-01 |
| 2020-09-30 | $595.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $13.32M derived: sum of 2 quarters · filed 2021-11-09 | $13.61M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $12.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $13.01M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $289.00K 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $1.13M 10-K · filed 2022-03-01 | |||
| 2019-06-30 | $607.00K 6-K · filed 2020-09-11 | |||
| 2018-12-31 | -$18.00K 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $1.62M 20-F · filed 2018-04-30 | |||
| 2016-12-31 | $716.84K 20-F · filed 2018-04-30 | |||
| 2015-12-31 | $61.60K 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |